14-day Premium Trial Subscription Try For FreeTry Free

Latest Data & Signals Issued

Signal Type Signal Value Data
Score 0.000 99 days ( -9.01 % )
Last Price $1.21 0 %
High/ Low $1.21 - $1.21 0%
Chg 7 Days N/A $1.21 $1.21
Chg 30 Days N/A $1.21 $1.21
Chg 12 mos -81.58 % $6.57 $1.21
Trend - 3 mos N/A Width: 0.00000000 %
Trend - 12 mos -29.79 % Width: 533.50 %
Pred. range - 3 mos $1.21 - $1.21 0 % - 0 %
Pred. range - 12 mos N/A - $5.00 -100.00 % - 313.40 %
Short MA avg 3 mos Sell Nov 30, -1 - N/A days
Long MA avg 3 mos Sell Feb 20, 2024 - 46 days
Short/Long MA avg 3 mos Sell Feb 20, 2024 - 46 days
Short MA avg 12 mos Sell Jan 30, 2024 - 60 days
Long MA avg 12 mos Buy Nov 30, 2023 - 100 days
Short/Long MA avg 12 mos Buy Nov 15, 2023 - 110 days
Pivot Short Sell Apr 23, 2024 - 2 days
Bollinger Sell Nov 30, -1 - N/A days
MACD N/A No Dates Stored For This Signal
Click to get the best stock tips daily for free!

About Rain Therapeutics Inc.

Rain Therapeutics. Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinica... RAIN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT